Literature DB >> 12383013

Synthesis, molecular modeling studies, and pharmacological activity of selective A(1) receptor antagonists.

Francesco Bondavalli1, Maurizio Botta, Olga Bruno, Andrea Ciacci, Federico Corelli, Paola Fossa, Antonio Lucacchini, Fabrizio Manetti, Claudia Martini, Giulia Menozzi, Luisa Mosti, Angelo Ranise, Silvia Schenone, Andrea Tafi, Maria Letizia Trincavellic.   

Abstract

We present a combined computational study aimed at identifying the three-dimensional structural properties required for different classes of compounds to show antagonistic activity toward the A(1) adenosine receptor (AR). Particularly, an approach combining pharmacophore mapping, molecular alignment, and pseudoreceptor generation was applied to derive a hypothesis of the interaction pathway between a set of A(1) AR antagonists taken from the literature and a model of the putative A(1) receptor. The pharmacophore model consists of seven features and represents an improvement of the N(6)-C8 model, generally reported as the most probable pharmacophore model for A(1) AR agonists and antagonists. It was used to build up a pseudoreceptor model able to rationalize the relationships between structural properties and biological data of, and external to, the training set. In fact, to further assess its statistical significance and predictive power, the pseudoreceptor was employed to predict the free energy of binding associated with compounds constituting a test set. While part of these molecules was also taken from the literature, the remaining compounds were designed and synthesized by our research group. All of the new compounds were tested for their affinity toward A(1), A(2a), and A(3) AR, showing interesting antagonistic activity and A(1) selectivity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12383013     DOI: 10.1021/jm0209580

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  3 in total

1.  Invited Lectures : Overviews Purinergic signalling: past, present and future.

Authors: 
Journal:  Purinergic Signal       Date:  2006-05-15       Impact factor: 3.765

2.  New pyrazolo-[3,4-d]-pyrimidine derivative Src kinase inhibitors lead to cell cycle arrest and tumor growth reduction of human medulloblastoma cells.

Authors:  Alessandra Rossi; Silvia Schenone; Adriano Angelucci; Martina Cozzi; Valentina Caracciolo; Francesca Pentimalli; Andrew Puca; Biagio Pucci; Raffaele La Montagna; Mauro Bologna; Maurizio Botta; Antonio Giordano
Journal:  FASEB J       Date:  2010-03-30       Impact factor: 5.191

3.  Insight into the Structural Determinants of Imidazole Scaffold-Based Derivatives as TNF-α Release Inhibitors by in Silico Explorations.

Authors:  Yuan Wang; Mingwei Wu; Chunzhi Ai; Yonghua Wang
Journal:  Int J Mol Sci       Date:  2015-08-25       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.